Clinical concerns and considerations for leucovorin use in autism spectrum disorder

Area of Science:

• Pediatric neurology
• Autism spectrum disorder research
• Nutritional neuroscience

Background:

• Cerebral folate deficiency (CFD) is linked to autism spectrum disorder (ASD).
• Autoantibodies blocking brain folate entry occur in 71% of ASD patients, causing CFD.
• Leucovorin increases brain folate, potentially bypassing antibody interference.

Purpose of the Study:

• Review current research on leucovorin for pediatric autism spectrum disorder (ASD).
• Guide clinicians on evaluating and treating children with ASD and CFD.
• Provide an overview of leucovorin's biological rationale, evidence, and limitations in ASD.

Main Methods:

• Literature review of studies on leucovorin and autism spectrum disorder.
• Analysis of evidence regarding cerebral folate deficiency (CFD) in ASD.
• Examination of clinical trial data and expert recommendations.

Main Results:

• Some studies show leucovorin reduces communication deficits in nonverbal ASD children with specific autoantibodies.
• Other studies report no symptom improvement with leucovorin treatment in ASD.
• The American Academy of Pediatrics (AAP) does not currently recommend leucovorin for ASD.

Conclusions:

• Increased requests for leucovorin prescriptions for ASD are noted due to social media and policy interest.
• Clinicians need a balanced understanding of leucovorin's potential benefits and limitations in pediatric ASD.
• Further research is needed to clarify leucovorin's efficacy and role in managing ASD.